RCI
STML

Ridgeback Capital Investments’s Stemline Therapeutics, Inc. STML Stock Holding History

Ridgeback Capital Investments’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-506,699
Closed -$9.93M – 5
2013
Q4 		$9.93M Buy
+506,699
New +$13.5M 12.55% 3

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ridgeback Capital Investments's STML Position: Q1 2014 in Review

Ridgeback Capital Investments sold out of Stemline Therapeutics, Inc. (STML) in Q1 2014, closing a stake of 506,699 shares — an estimated $9.93M sold.

Ridgeback Capital Investments first reported a position in STML in Q4 2013 and held it in 1 quarter. The position peaked at $9.93M in Q4 2013. 61 funds tracked by Wall St. Rank hold STML as of Q1 2014.

  • Ridgeback Capital Investments reported no remaining Stemline Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Ridgeback Capital Investments sold 506,699 Stemline Therapeutics, Inc. shares in Q1 2014, an estimated $9.93M.
  • Ridgeback Capital Investments first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 1 quarter.
  • Ridgeback Capital Investments's Stemline Therapeutics, Inc. position peaked at $9.93M in Q4 2013.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2014.

Based on Ridgeback Capital Investments's 13F filing for Q1 2014.